Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep;74(3):243-245.
doi: 10.1016/j.eururo.2018.05.027. Epub 2018 Jun 13.

Prognosis, Effect Modification, and Mediation

Andrew J Vickers  1 , Gunnar Steineck  2
Affiliations
Editorial

Prognosis, Effect Modification, and Mediation

Andrew J Vickers et al. Eur Urol. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Absolute reduction in risk of death at 10 yr associated with surgery by age. Grey line: Gleason 8+; Dashed line: Gleason 7; Black line: Gleason 6.
Fig. 2
Fig. 2
Probability of an adverse outcome (eg, death) in a randomized trial plotted against the level of an adverse risk factor (eg, prostate-sdoubling time at recurrence). Black line: Control group. Light grey: Treatment group where treatment has a constant relative risk reduction, a 50% reduction in risk. Dashed line: Treatment group where treatment is associated with a constant absolute risk reduction of 5%. Note that if relative risk reduction is constant different levels of the prognostic factor, absolute risk reduction varies and vice versa.
See this image and copyright information in PMC

References

    1. Steineck G, Adolfsson J, Scher HI, Whitmore WF Jr., Distinguishing prognostic and treatment-predictive information for localized prostate cancer. Urology 1995;45:610–5. - PubMed
    1. Schmidt AF, Klungel OH, Nielen M, de Boer A, Groenwold RH, Hoes AW. Tailoring treatments using treatment effect modification. Pharmacoepidemiol Drug Saf 2016;25:355–62. - PubMed
    1. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol 2013;42:1012–4. - PMC - PubMed
    1. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–42. - PMC - PubMed
    1. Vickers A, Bennette C, Steineck G, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012;62:204–9. - PMC - PubMed

Publication types

MeSH terms